However, the multiple assays above (Figs. 1D, F and G and 2 C) for antibody uptake across different cancer cell lines (DLD-1, DLD-1 BRCA2, HCT116, MDA-MB-231, and CT26) consistently show robust cell penetration and nuclear localization of the antibody in all the cancer lines tested, suggesting that there is sufficient ENT2 expression in all these tumor cell lines to support strong antibody penetration. This evidence concerns the gene SLC29A2 and neoplasm.